Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 135, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111235
Keywords
Nonalcoholic fatty liver disease; Alcoholic liver disease; Intestinal microbiota; Intervention
Funding
- National Natural Science Foundation of China [81600483, 82003933]
- Six Talent Peaks Project in Jiangsu Province [WSN-102]
- Nanjing Medical Science and technique Development Foundation [QRX17190, YKK17153, ZKX19034]
- Chinese Foundation for Hepatitis Prevention and Control Tianqing Hepatology Research Foundation [TQGB20170027, TQGB20140235]
- Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX19_1257]
- Nanjing Youth Talent Training Plan of TCM [ZYQ20006]
Ask authors/readers for more resources
Liver diseases such as NAFLD and ALD are on the rise globally, with a close relationship to the intestinal microbiota. Understanding the role of intestinal microbiota and the gut-liver axis may lead to novel therapeutic approaches for these diseases.
Introduction: Liver diseases are currently common disorders worldwide. Especially, the proportion of patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is growing globally. An increasing number of studies have revealed a close relationship between the intestinal microbiota and the development of NAFLD and ALD. A better understanding of the role of intestinal microbiota and the intestine liver axis thus might lead to the development novel therapies for the treatment of these diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
